Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$27,000.00
Using extracellular vesicles as secondary delivery vehicles for messenger RNA (mRNA) immunotherapy for solid tumours
EF 2024-25
Résumé
Solid tumours are tissue masses that occur in many different cancers, including triple-negative breast cancer (TNBC), a highly aggressive form of breast cancer. It is difficult to treat solid tumours because many treatments cannot pass through the tissue layers of the tumour effectively. mRNA therapeutics are no exception. mRNA can be used to stimulate the immune system to destroy the cancer in various ways. One promising method involves encoding an oncolytic protein that punctures the cell membrane of cancer cells, promoting cancer cell death and the release of cell components that can stimulate the immune system. However, this technology can be improved by increasing the number of cancer cells in the tumour that receive the therapeutic mRNA. We hypothesize that packaging the therapeutic mRNA into extracellular vesicles (EVs) inside cancer cells following delivery using a lipid nanoparticle (LNP) can help deliver the therapeutic mRNA to more cancer cells in all parts of the tumour, increasing cancer cell death and stimulating the immune response more effectively against the tumour. EVs can pass many biological barriers, preferentially target cells similar to their secreting cell, and are produced at high levels by cancer cells, making them great candidates for secondary delivery vehicles of therapeutic mRNA. First, we will validate the ability of the mRNA-encoded EV packaging systems to effectively package therapeutic mRNA into EVs as well as the ability of the EVs carrying the therapeutic mRNA to transfect more cancer cells in 2D cell culture of TNBC compared to LNP delivery alone. Next, we will measure the efficacy of this system in 2D and 3D in vitro modelsof TNBC in the hopes of demonstrating that this system can improve mRNA delivery within the tumour.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
530330
Name
Savguira Margarita
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Using extracellular vesicles as secondary delivery vehicles for messenger RNA (mRNA) immunotherapy for solid tumours
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cell-Mediated Mrna Secretion; Extracellular Vesicles; Immunotherapy; Lipid Nanoparticles; Mrna Delivery; Mrna Therapy; Solid Tumours; Triple Negative Breast Cancer; Tumour Microenvironment
Abstract
Solid tumours are tissue masses that occur in many different cancers, including triple-negative breast cancer (TNBC), a highly aggressive form of breast cancer. It is difficult to treat solid tumours because many treatments cannot pass through the tissue layers of the tumour effectively. mRNA therapeutics are no exception. mRNA can be used to stimulate the immune system to destroy the cancer in various ways. One promising method involves encoding an oncolytic protein that punctures the cell membrane of cancer cells, promoting cancer cell death and the release of cell components that can stimulate the immune system. However, this technology can be improved by increasing the number of cancer cells in the tumour that receive the therapeutic mRNA. We hypothesize that packaging the therapeutic mRNA into extracellular vesicles (EVs) inside cancer cells following delivery using a lipid nanoparticle (LNP) can help deliver the therapeutic mRNA to more cancer cells in all parts of the tumour, increasing cancer cell death and stimulating the immune response more effectively against the tumour. EVs can pass many biological barriers, preferentially target cells similar to their secreting cell, and are produced at high levels by cancer cells, making them great candidates for secondary delivery vehicles of therapeutic mRNA. First, we will validate the ability of the mRNA-encoded EV packaging systems to effectively package therapeutic mRNA into EVs as well as the ability of the EVs carrying the therapeutic mRNA to transfect more cancer cells in 2D cell culture of TNBC compared to LNP delivery alone. Next, we will measure the efficacy of this system in 2D and 3D in vitro modelsof TNBC in the hopes of demonstrating that this system can improve mRNA delivery within the tumour.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Savguira, Margarita
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~